▶ 調査レポート

短腸症候群の世界市場:薬物クラス別(グルカゴン類似ペプチド2(GLP-2)、成長ホルモン、グルタミン、その他)

• 英文タイトル:Short Bowel Syndrome Market (Drug Class: Glucagon-like Peptide-2 (GLP-2), Growth Hormone, Glutamine, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027

Transparency Market Researchが調査・発行した産業分析レポートです。短腸症候群の世界市場:薬物クラス別(グルカゴン類似ペプチド2(GLP-2)、成長ホルモン、グルタミン、その他) / Short Bowel Syndrome Market (Drug Class: Glucagon-like Peptide-2 (GLP-2), Growth Hormone, Glutamine, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027 / D0JU09131資料のイメージです。• レポートコード:D0JU09131
• 出版社/出版日:Transparency Market Research / 2020年1月20日
• レポート形態:英文、PDF、176ページ
• 納品方法:Eメール
• 産業分類:製薬
• 販売価格(消費税別)
  Single User¥764,940 (USD5,795)▷ お問い合わせ
  Multi User¥1,160,940 (USD8,795)▷ お問い合わせ
  Corporate License¥1,556,940 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、短腸症候群の世界市場について調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、キーインサイト、薬物クラス別(グルカゴン類似ペプチド2(GLP-2)、成長ホルモン、グルタミン、その他)分析、地域別分析、競争状況などの構成でお届けいたします。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・キーインサイト
・短腸症候群の世界市場:薬物クラス別(グルカゴン類似ペプチド2(GLP-2)、成長ホルモン、グルタミン、その他)
・短腸症候群の世界市場:地域別
・競争状況

Short Bowel Syndrome Market – Scope of the Report

TMR’s report on the global short bowel syndrome market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the market during the forecast period from 2019 to 2027. The report provides the revenue of the short bowel syndrome market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the short bowel syndrome market for the forecast period. The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global short bowel syndrome market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of top-down and bottom-up approaches to study various phenomena in the short bowel syndrome market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the short bowel syndrome market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the short bowel syndrome market. The next section of the short bowel syndrome report highlights the USPs, which include drivers & restraints impact analysis, value chain analysis; short bowel syndrome disease overview, short bowel syndrome epidemiology, rare diseases prevalence, overview of clinical trials for short bowel syndrome, qualitative analysis of glp-2 product, research & development cost analysis, impact analysis of clinical trials cost on orphan drugs, cost analysis of therapies using orphan drugs, approved U.S. orphan indications, 1983–2015, approved European orphan indications, 2019, pricing analysis, orphan drugs – price volume analysis, justifications for the high cost of Gattex & Teduglutide, regulations scenario assessment, flow chart guide to determine eligibility for standard orphan designation in Australia, impact analysis of regulatory scenario assessment, comparative analysis of orphan drug policies, orphan drug manufacturing companies, acquisitions timeline, and SWOT analysis.

The report analyzes the short bowel syndrome market in terms of drug class and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2027 has been provided. These valuable insights would help market stakeholders in making informed business decisions for investments in the short bowel syndrome market.

Key Questions Answered in Short Bowel Syndrome Market Report

What is the sales/revenue generated by different short bowel syndrome (SBS) across all the regions during the forecast period?
What are the major drivers, restraints, and opportunities in the market?
Which region is set to expand at the fastest CAGR during the forecast period?
Which segment will have the highest revenue globally in 2027 and which product will expand at the fastest CAGR during the forecast period?
Short Bowel Syndrome Market – Research Objectives and Research Approach

The comprehensive report on the short bowel syndrome market begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of the study and healthcare compliances laid down by accredited agencies in the purview of research in the short bowel syndrome market. It is followed by market introduction, market dynamics, and an overview of the short bowel syndrome market, which includes TMR analysis of market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends of the short bowel syndrome market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Revenue generated by key short bowel syndrome market manufacturers has been mapped to ascertain the size of the short bowel syndrome market in terms of value. The forecast presented here assesses the total revenue generated by dermatome devices. In order to provide an accurate forecast, we initiated by sizing up the current short bowel syndrome market with the help of the parent market.

The report also delves into the competitive landscape of the short bowel syndrome market. Key players operating in the short bowel syndrome treatment market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the short bowel syndrome treatment market report.

Key players operating in the short bowel syndrome market include Shire plc (Takeda Pharmaceutical Company Limited), Zealand Pharma A/S, Sancilio & Company, Inc., OxThera, Nutrinia Ltd., Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc. (Pfizer Inc.), Merck KGaA, and Naia Pharmaceuticals, Inc.

レポート目次

1. Preface

1.1. Report Scope and Market Segmentation

1.2. Research Highlights

2. Assumptions and Research Methodology

2.1. Assumptions and Acronyms Used

2.2. Research Methodology

3. Executive Summary

3.1. Global Short Bowel Syndrome Market: Market Snapshot

4. Market Overview

4.1. Global Short Bowel Syndrome Market: Type Overview

4.2. Global Short Bowel Syndrome Market: Key Industry Developments

4.3. Market Dynamics

4.4. Drivers and Restraints Snapshot Analysis

4.5. Drivers

4.5.1. High cost of parenteral nutrition increases demand for SBS drugs

4.5.2. Favorable reimbursement scenario

4.6. Restraints

4.6.1. Side effects associated with SBS drugs

4.6.2. Non-availability of approved drugs globally

4.7. Opportunities

4.8. Global Short Bowel Syndrome Market Revenue Projections (US$ Mn), 2017–2027

5. Key Insights

5.1. Drivers & Restraints Impact Analysis

5.2. Value Chain Analysis

5.3. Short Bowel Syndrome: Disease Overview

5.4. Short Bowel Syndrome: Epidemiology

5.5. Rare Diseases Prevalence

5.6. Overview of Clinical Trials for Short Bowel Syndrome

5.7. Qualitative Analysis of GLP-2 Product

5.8. Research & Development Cost Analysis

5.9. Impact Analysis of Clinical Trials Cost on Orphan Drugs

5.10. Cost Analysis of Therapies using Orphan Drugs

5.11. Approved U.S. Orphan Indications, 1983–2015

5.12. Approved European Orphan Indications, 2019

5.13. Pricing Analysis

5.14. Orphan Drugs – Price Volume Analysis

5.15. Justifications for the High Cost of Gattex & Teduglutide

5.16. Regulations Scenario Assessment

5.17. Flow Chart Guide to Determine Eligibility for Standard Orphan Designation in Australia

5.18. Impact Analysis of Regulatory Scenario Assessment

5.19. Comparative Analysis of Orphan Drug Policies

5.20. Orphan Drug Manufacturing Companies – Acquisitions Timeline

5.21. Orphan Drugs Market- SWOT Analysis

6. Global Short Bowel Syndrome Market Analysis, by Drug Class

6.1. Introduction

6.2. Global Short Bowel Syndrome Market Value and Forecast, by Drug Class

6.2.1. Glucagon-like Peptide-2 (GLP-2)

6.2.2. Growth Hormone

6.2.3. Glutamine

6.2.4. Others

6.3. Global Short Bowel Syndrome Market Analysis, by Drug Class

6.4. Global Short Bowel Syndrome Market Attractiveness Analysis, by Drug Class

7. Global Short Bowel Syndrome Market Analysis, by Region

7.1. Global Short Bowel Syndrome Market Value and Forecast, by Region, 2017–2027

7.1.1. North America

7.1.2. Europe

7.1.3. Japan

7.1.4. Rest of the World

7.2. Global Short Bowel Syndrome Market Analysis, by Region

7.3. Global Short Bowel Syndrome Market Attractiveness Analysis, by Region

8. North America Short Bowel Syndrome Market Analysis

8.1. North America Short Bowel Syndrome Market

8.2. North America Short Bowel Syndrome Market Overview

8.3. North America Short Bowel Syndrome Market Value and Forecast, by Drug Class

8.3.1. Glucagon-like Peptide-2 (GLP-2)

8.3.2. Growth Hormone

8.3.3. Glutamine

8.3.4. Others

8.4. North America Short Bowel Syndrome Market Forecast, by Country

8.4.1. U.S.

8.4.2. Canada

8.5. North America Short Bowel Syndrome Market Attractiveness Analysis

8.5.1. By Drug Class

8.5.2. By Country

9. Europe Short Bowel Syndrome Market Analysis

9.1. Europe Short Bowel Syndrome Market

9.2. Europe Short Bowel Syndrome Market Overview

9.3. Europe Short Bowel Syndrome Market Value and Forecast, by Drug Class

9.3.1. Glucagon-like Peptide-2 (GLP-2)

9.3.2. Growth Hormone

9.3.3. Glutamine

9.3.4. Others

9.4. Europe Short Bowel Syndrome Market Forecast, by Country/Sub-region

9.4.1. U.K.

9.4.2. France

9.4.3. Germany

9.4.4. Spain

9.4.5. Italy

9.4.6. Rest of Europe

9.5. Europe Short Bowel Syndrome Market Attractiveness Analysis

9.5.1. By Drug Class

9.5.2. By Country/Sub-region

10. Japan Short Bowel Syndrome Market Analysis

10.1. Japan Short Bowel Syndrome Market Key Findings

10.2. Japan Short Bowel Syndrome Market Overview

10.3. Japan Short Bowel Syndrome Market Value and Forecast, by Drug Class

10.3.1. Glucagon-like Peptide-2 (GLP-2)

10.3.2. Growth Hormone

10.3.3. Glutamine

10.3.4. Others

10.4. Japan Short Bowel Syndrome Market Attractiveness Analysis, by Drug Class

11. Rest of the World Short Bowel Syndrome Market Analysis

11.1. Rest of the World Short Bowel Syndrome Market Key Findings

11.2. Rest of the World Short Bowel Syndrome Market Overview

11.3. Rest of the World Short Bowel Syndrome Market Value and Forecast, by Drug Class

11.3.1. Glucagon-like Peptide-2 (GLP-2)

11.3.2. Growth Hormone

11.3.3. Glutamine

11.3.4. Others

11.4. Rest of the World Short Bowel Syndrome Market Analysis, by Country/Sub-region

11.4.1. China

11.4.2. India

11.4.3. Australia/New Zealand

11.4.4. Middle East

11.4.5. Brazil

12. Competitive Landscape

12.1. Company Profiles

12.1.1. Shire plc (Takeda Pharmaceutical Company Limited)

12.1.1.1. Overview (HQ, Employee Strength, Business Segments)

12.1.1.2. Financials

12.1.1.3. Recent Developments

12.1.1.4. Strategy

12.1.2. Zealand Pharma A/S

12.1.2.1. Overview (HQ, Employee Strength, Business Segments)

12.1.2.2. Financials

12.1.2.3. Recent Developments

12.1.2.4. Strategy

12.1.3. Sancilio & Company, Inc.

12.1.3.1. Overview (HQ, Employee Strength, Business Segments)

12.1.3.2. Recent Developments

12.1.3.3. Strategy

12.1.4. OxThera

12.1.4.1. Overview (HQ, Employee Strength, Business Segments)

12.1.4.2. Recent Developments

12.1.4.3. Strategy

12.1.5. Nutrinia Ltd

12.1.5.1. Overview (HQ, Employee Strength, Business Segments)

12.1.5.2. Recent Developments

12.1.5.3. Strategy

12.1.6. Ardelyx, Inc.

12.1.6.1. Overview (HQ, Employee Strength, Business Segments)

12.1.6.2. Financials

12.1.6.3. Recent Developments

12.1.6.4. Strategy

12.1.7. Emmaus Life Sciences, Inc.

12.1.7.1. Overview (HQ, Employee Strength, Business Segments)

12.1.7.2. Financials

12.1.7.3. Recent Developments

12.1.7.4. Strategy

12.1.8. GLyPharma Therapeutic, Inc. (Pfizer Inc.)

12.1.8.1. Overview (HQ, Employee Strength, Business Segments)

12.1.8.2. Financials

12.1.8.3. Recent Developments

12.1.8.4. Strategy

12.1.9. Merck KGaA

12.1.9.1. Overview (HQ, Employee Strength, Business Segments)

12.1.9.2. Financials

12.1.9.3. Recent Developments

12.1.9.4. Strategy

12.1.10. Naia Pharmaceuticals, Inc.

12.1.10.1. Overview (HQ, Employee Strength, Business Segments)

12.1.10.2. Recent Developments

12.1.10.3. Strategy

List of Tables

TABLE 1 Overview of Clinical Trials for Short Bowel Syndrome (1/2)

TABLE 2 Overview of Clinical Trials for Short Bowel Syndrome (2/2)

TABLE 3 Orphan Drugs Research & Development Cost (US$ Mn), 2014–2018

TABLE 4 Impact Analysis of Clinical Trials Cost on Orphan Drugs (1/2)

TABLE 5 Impact Analysis of Clinical Trials Cost on Orphan Drugs (2/2)

TABLE 6 Comparative Analysis of Orphan Drug Policies

TABLE 7 Global Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

TABLE 8 Global Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Region, 2019–2027

TABLE 9 North America Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

TABLE 10 North America Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Country, 2017–2027

TABLE 11 Europe Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027

TABLE 12 Europe Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

TABLE 13 Japan Short Bowel Syndrome (SBS) Market Value (US$ Mn) Forecast, by Drug Class, 2017–2027